Noxopharm aims for autoimmune market with first human trial of SOF-SKN
Noxopharm Ltd is planning the first human trial to assess novel drug SOF-SKN, which aims to treat autoimmune conditions.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
ICH | Ann: Removal from Official List at close 16/11/20 | 16/11/11 | 0 | 503 | |||
|
|||||||
ICH | Ann: iSelect Ltd takes operational control of Inf | 14/11/11 | 0 | 430 | |||
|
|||||||
ICH | Ann: Suspension from Official Quotation at close | 11/11/11 | 0 | 477 | |||
|
|||||||
ICH | Ann: Letter to Shareholders - compulsory acquisit | 04/11/11 | 0 | 432 | |||
|
|||||||
ICH | Ann: Close of Takeover Offer | 02/11/11 | 0 | 438 | |||
|
|||||||
ICH | Ann: Appendix 4C - quarterly | 31/10/11 | 0 | 309 | |||
|
|||||||
ICH | Ann: Notice pursuant to Sec 630(3) Status of Defe | 21/10/11 | 0 | 317 | |||
|
|||||||
ICH | Ann: iSelect Offer Declared Unconditional | 13/10/11 | 0 | 374 | |||
|
See All Discussions